Lakewood-Amedex Biotherapeutics Inc. (LABT)
Nasdaq: LABT · Pharmaceutical Preparations · filing with the SEC since 2025
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal quarter | Q2 FY26 | Q1 FY26 |
|---|---|---|
| Period ending | Jun 30, 2026 | Mar 31, 2026 |
| Report filed | Aug 14, 2026 | May 22, 2026 |
| Cost of revenue | · | 507,292 |
| Research and development | 503,020 | 182,147 |
| General and administrative | 3,285,481 | 703,444 |
| Total operating expenses | 3,789,660 | 886,750 |
| Operating income | -3,789,660 | -886,750 |
| Interest expense | 10,633 | 38,219 |
| Interest and investment income | 28,285 | 1,078 |
| Total non-operating income (expense) | 17,652 | -36,541 |
| Net income | -3,772,008 | -923,291 |
| Net income to common shareholders | 3,898,045 | 1,416,481 |
| Earnings per share, basic | -2.75 | -0.20 |
| Earnings per share, diluted | -2.75 | -0.20 |
| Weighted average shares, basic | 1,419,767 | 6,995,469 |
| Weighted average shares, diluted | 1,419,767 | 6,995,469 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Cost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding